Checkpoint Blockade + Chemotherapy: the Right Combination for AML?

Spencer C. Wei; James J. Mancuso; Naval Daver; James P. Allison

doi:10.1158/2643-3230.BCD-21-0130

Checkpoint Blockade + Chemotherapy: the Right Combination for AML?

Spencer C. Wei, James J. Mancuso, Naval Daver, James P. Allison

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.

Original language	English (US)
Pages (from-to)	551-554
Number of pages	4
Journal	Blood cancer discovery
Volume	2
Issue number	6
DOIs	https://doi.org/10.1158/2643-3230.BCD-21-0130
State	Published - Nov 1 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/2643-3230.BCD-21-0130

Cite this

@article{4adbf44fd8214e5ca6220943c4bed56e,

title = "Checkpoint Blockade + Chemotherapy: the Right Combination for AML?",

abstract = "An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.",

author = "Wei, {Spencer C.} and Mancuso, {James J.} and Naval Daver and Allison, {James P.}",

note = "Publisher Copyright: {\textcopyright}2021 American Association for Cancer Research.",

year = "2021",

month = nov,

day = "1",

doi = "10.1158/2643-3230.BCD-21-0130",

language = "English (US)",

volume = "2",

pages = "551--554",

journal = "Blood cancer discovery",

issn = "2643-3230",

number = "6",

}

TY - JOUR

T1 - Checkpoint Blockade + Chemotherapy

T2 - the Right Combination for AML?

AU - Wei, Spencer C.

AU - Mancuso, James J.

AU - Daver, Naval

AU - Allison, James P.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.

AB - An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85147461238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147461238&partnerID=8YFLogxK

U2 - 10.1158/2643-3230.BCD-21-0130

DO - 10.1158/2643-3230.BCD-21-0130

M3 - Article

C2 - 35015675

AN - SCOPUS:85147461238

SN - 2643-3230

VL - 2

SP - 551

EP - 554

JO - Blood cancer discovery

JF - Blood cancer discovery

IS - 6

ER -

Checkpoint Blockade + Chemotherapy: the Right Combination for AML?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this